Skip to Content

Surprising result for the treatment of moderate to severe AD with lebrikizumab

During this MEDtalk, Andrew Blauvelt discusses the recently published 52-week data on the effectiveness and safety of lebrikizumab in treating moderate to severe atopic dermatitis (AD). The study reveals unexpectedly positive results, showing sustained improvements in all measured outcomes.

Andrew  Blauvelt

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top